Postmenopausal hormone therapy and cancer risk
|
|
- Emmeline Melton
- 5 years ago
- Views:
Transcription
1 International Congress Series 1279 (2005) Postmenopausal hormone therapy and cancer risk P. Kenemans*, R.A. Verstraeten, R.H.M. Verheijen Department of Obstetrics and Gynaecology, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands Abstract. Postmenopausal Hormone Replacement Therapy has been implicated in the development of four frequent female tumors: endometrial cancer, breast cancer, ovarian cancer and colorectal cancer. Estrogens are only weak genotoxic, mutagenic carcinogens, but could induce tumors by way of accumulation of incessant DNA replication damage. While estrogen (only) hormone replacement therapy (ERT) increases the risk of endometrial carcinoma and probably of ovarian carcinoma, ERT seems to be neutral for the breast and colorectal cancer. With combined estrogen progestagen replacement therapy (HRT), there is no increased risk of endometrial cancer nor of ovarian cancer. The risk of breast cancer, however, is slightly increased with long-term use. Colorectal cancer risk is probably reduced with combined HRT use. Data are only available for oral use; for transdermal, intranasal and other use no data are available. D 2005 Elsevier B.V. All rights reserved. Keywords: Estrogens; Progestagens; HRT; Cancer risk; Breast cancer 1. Introduction In postmenopausal women the risk of cancer increases with age [1]. Breast cancer is the most common malignancy in women. Worldwide, endometrial carcinoma is the second most common gynecological cancer after breast carcinoma, while ovarian cancer is the main cause of death among the gynecological malignancies. Colorectal cancer is the most frequent neoplasm among non-smoking women in the Western world, and in the United States it is the third highest cause of death after lung and breast cancers, respectively. * Corresponding author. address: Kenemans@vumc.nl (P. Kenemans) / D 2005 Elsevier B.V. All rights reserved. doi: /j.ics
2 134 P. Kenemans et al. / International Congress Series 1279 (2005) Endogenous as well as exogenous sex hormones have been implicated in the development of these four frequent tumors. 2. Endometrial cancer The large majority of endometrial carcinomas is hormone dependent. Both in premenopausal and in postmenopausal women, prolonged unopposed estrogen stimulation plays a major role. As shown in a meta-analysis by Grady [2], the overall relative risk (RR) of developing endometrial cancer for ever-users of estrogenonly hormone replacement therapy (ERT) was doubled compared with never-users. The same analysis showed a risk increasing over time with duration of ERT use. For patients who stop their estrogen-only replacement therapy, the increased risk persists for many years (at least 5 years) after the treatment. A number of additional factors are recognized which may increase the risk of endometrial cancer in ERT users. The excess risk may be larger in lean women, non-smokers and in women that never used oral contraceptives. The addition of a progestogen, the combined hormone replacement therapy (HRT), substantially reduces the risk of developing endometrial cancer [2]. However, the use of a sequential regimen for long periods of treatment has generated some worries and doubts. An American study of women treated with sequential HRT reported an increased risk (RR 2.5, 95% CI ) for periods of use longer than 5 years, even when a progestagen was used 10 days or more each month [3]. The importance of adequate progestogen combination length in offering sufficient endometrial protection was shown in another American study [4]. Women treated with a sequential HRT regimen with progestogens for at least 10 days per month (10 up to 21 days/month) did not show any significant increase in endometrial cancer risk (RR 1.1, 95% CI ). Various observational studies show that continuous combined regimens provide sufficient endometrial protection or even might reduce the risk of endometrial cancer [4 6]. Also prospective, randomized trials like the Hers study [7] and the Women s Health Initiative (WHI) study [8] provide evidence as to the neutrality of a continuous combined regimen on the endometrium. In summary, for non-hysterectomized women, unopposed estrogen use greatly increases the risk of endometrial cancer. This risk is greatly reduced by combining a progestogen with the estrogen in a sequential regimen. The continuous use of a progestogen may even reduce the risk of endometrial cancer [5]. 3. Ovarian cancer Ovarian cancer cells express various types of sex hormone receptors. In a review of the available evidence on ovarian cancer, Drew et al. [9] showed that the results from studies on ovarian cancer with HRT are discordant. While unopposed estrogen therapy may increase risk, many studies with combined estrogen/progestogen show no increased risk of developing ovarian cancer [9]. Also, two meta-analyses [10,11] and two observational studies [12,13] do not indicate a strong positive correlation between HRT and ovarian cancer. The role of HRT duration on risk is still debated. In a meta-analysis by Garg et al. [10], the use of HRT for more than 10 years was associated with a slight risk increase (RR 1.15, 95% CI ), whereas
3 P. Kenemans et al. / International Congress Series 1279 (2005) Coughlin et al. [11] did not report any correlation between HRT use and incidence of ovarian cancer (RR 1.1, 95% CI ). Great uncertainty surrounds the conclusion from studies that have analyzed ovarian cancer mortality in relation to HRT. In fact, an earlier study [14] did not observe any increase in mortality among women using HRT, while the higher mortality observed among women treated for more than 10 years in a recent study [12] caused great astonishment. Relative risk for former use was 1.59 (95% CI ) and for current use 2.20 (95% CI ). Despite the remarkable number of cases considered and the noteworthy observational period (14 years) of this American study, data on HRT use for more than 10 years in this trial was derived from only 66 cases of ovarian cancer. In conclusion, it would seem that high-dose ERT for many years would increase the risk for ovarian cancer. There is no evidence that modern combined use would increase the risk for ovarian cancer. 4. Breast cancer Many known risk factors for breast cancer are hormonal in nature. A reanalysis of over 90% of the world literature on the relationship between estrogen use and breast cancer published in the Lancet in 1997 reviewed 51 epidemiological studies with over 52,000 women with breast cancer and over 108,000 women without [15]. This reanalysis shows that in women who use hormones breast cancer risk increases from the basal individual risk by 2.3% for each year of HRT use. The same applies for a delay in onset of menopause. Annual breast cancer risk increases by 2.8% for each year of delayed menopause [15]. Fig. 1 shows the absolute increase in risk of breast cancer as taken from the Lancet reanalysis. In North America and Europe, the cumulative incidence of breast cancer between the ages of 50 and 70 years in HRT never-users is about 77 per 1000 women. The cumulative excess numbers of breast cancers diagnosed between these ages per 1000 women who Cumulative incidence per 1000 women never use use for 5 years use for 10 years 77 use for 15 years Age (years) Fig. 1. Estimate of increase in cumulative number of breast cancer per 1000 post-menopausal women using hormone replacement therapy for 0, 5, 10 and 15 years, respectively, all having started at age 50. Modified after Beral et al. [15], with permission.
4 136 P. Kenemans et al. / International Congress Series 1279 (2005) began HRT use at 50 and used it for 5, 10 and 15 years are estimated to be 2, 6 and 12, respectively. This excess risk reduces after HRT use ceases and largely disappears after 5 years [15]. Cohort studies on breast cancer risk with long-term use show a difference in breast cancer risk between ERT and combined HRT regimens. There appears to be a negative effect of addition of a progestogen compared with estrogen alone [16 23]. Case control studies analyzing the difference in breast cancer risk between unopposed estrogen use and combined HRT give the same picture [24 28]. There is a negative effect of estrogen progestogen combinations on the breast compared with estrogen alone. Studies [19 22,24 29] analyzing the difference of breast cancer risk between unopposed estrogen (ERT) and the two forms of combined HRT in the same population seem to indicate that, in general, the effect of continuous combined regimens on the breast might be stronger than that of sequential combined regimens (Table 1). Data from the two prospective, placebo-controlled studies [7,30] showed a RR of approximately 1.25 among women treated with continuous combined HRT; the increase in risk became significant for HRT use longer than 4 years [30]. The increase in risk of breast cancer with HRT use seems to be restricted to lean women (BMIb25.0). Overweight postmenopausal women have already achieved the maximum hormone-related risk increase due to their endogenous production of estrogens, and HRT use is not increasing this risk further [15,18]. In the reanalysis [15], use for 5 years and over did not increase risk in women with a BMI of 25 and over (RR 1.02), however, it did in women with a BMIb25 (RR 1.52). The Million Women Study, the MWS [20], is a retrospective cohort study of 1,084,110 British women aged 50 to 64 years participating in the National Breast Cancer Screening Programme that was set up to investigate the effects of various patterns of use of HRT on incident and fatal breast cancer. In this trial, current use of HRT was associated with an increased risk of both incident as well as fatal breast cancer; the effect was substantially greater for estrogen progestogen combinations (RR 2.0 (95% CI )) than for ERT (RR 1.3 (95% CI )). Table 1 Breast cancer risk with different regimens of postmenopausal HT in the same population Study Study type Number OR ERT OR schrt OR cchrt Reference of cases Magnusson (1999) case-control a a [24] Ross (2000) case-control a 1.09 [25] Chen (2002) case-control a 1.62 a 1.85 a [26] Newcomb (2002) case-control a a [27] Weiss (2002) case-control a [28] Porch (2002) cohort 411 b a [19] Olsson (2003) cohort c 1.44 c 3.13 a,c [21] Li (2003) case-control a 2.20 a [29] MWS (2003) cohort a 2.12 a 2.40 a [20] Stahlberg (2004) cohort a 1.94 a 4.16 a [22] a pb0.05. b Including 73 in situ cancers. c Hazard rate.
5 P. Kenemans et al. / International Congress Series 1279 (2005) The MWS is a very large study with 3202 breast cancer cases in 285,987 current hormone users. However, this does not compensate for the suboptimal observational design of the study, with a substantial detection and enrollment bias [31 33]. In the MWS, current continuous combined HRT use was associated with a larger risk increase for breast cancer (RR 2.12) than for sequential combined estrogen progestogen use (RR 2.40). Remarkably, risk increases were observed after just 1 year s exposure, and had almost disappeared 1 year after treatment discontinuation. In contrast to the recent data of the WHI [35], the patients included in the ERT arm of the MWS showed a significant increase in breast cancer risk, while the WHI found a non-significant decrease in risk (RR 0.77 (95% CI ). In contrast to the more increased relative risk observed in combined estrogen progestogen users in the MWS (RR 2.40), the relative risk increase with continuous combined treatment as found in the prospective randomised WHI trial (after 5.2 years of use) was only 24% (RR 1.24 (95% CI )). So the MWS has probably overestimated potential risks. Thus, in contrast to prospective, randomised trials like Hers [7] and WHI [30,35], the MWS [20] shows a substantial overestimation of the relative risk for breast cancer, both for that with ERT [35] as well as that with HRT [7,30]. 5. Colorectal cancer Many cohort and case control studies have reported a substantial reduction in colorectal cancer risk among women using HRT. Such a positive outcome varies from 20% to 40% and is higher among women who have recently used hormones [36,37]. A meta-analysis that specifically addressed the relationship between HRT and colon cancer showed that recent use (either at the time of assessment or within the previous year) was associated with an RR of 0.67 (95% CI ) of developing this malignancy [36]. Protection was limited to recent users. In another meta-analysis on 20 studies [37], the overall RR among ever users was 0.8 (95% CI ) and 0.66 (95% CI ) for current HRT users. This protective effect of HRT significantly decreased after stopping treatment. Clinical controlled studies like HERS [7] and WHI [8] studies confirm the protective role of combined HRT on colorectal cancer. In the WHI trial [8], the incidence rate of colorectal cancer in treated women was significantly reduced by 37% (RR 0.63 (95% CI )). In terms of absolute excess risk per 10,000 person years, attributable to continuous combined HRT use, this means six fewer colorectal cancers, but 8 more breast cancers. Remarkably, in the WHI [35] ERT use did not reduce colon cancer risk (excess risk per 10,000 person years: 1 case), but did reduce breast cancer risk (7 cases less per 10,000 person years). The overall results of the trial show that there was neither an increase in relative risk of total cancer in HRT users (RR 1.03, 95% CI ), nor in total mortality (RR 0.93 ( )). The fact that postmenopausal hormone use does not increase mortality had been shown earlier in large cohort studies [38 41].
6 138 P. Kenemans et al. / International Congress Series 1279 (2005) Table 2 Mortality in HT users Studies All causes Myocardial All cancers Breast cancer Colon cancer Reference infarction Hunt et al [38] (1990) ( ) ( ) ( ) ( ) Sturgeon [39] et al. (1995) ( ) ( ) ( ) (0.5 1) ( ) Schairer [41] et al. (1997) ( ) ( ) ( ) ( ) ( ) Grodstein [40] et al. (1997) Current use 0.58 ( ) 0.35 ( ) 0.67 ( ) 0.77 ( ) Past use 1.00 ( ) 0.84 ( ) 1.01 ( ) 0.80 ( ) RR (95% CI) in cohort studies with at least 200 deaths in HT users. Table 2 represents the relative risk of mortality demonstrated in cohort studies using ERT/HRT, in which at least 200 deaths were recorded in ever-users. Overall, in terms of mortality, the results with ERT/HRT are beneficial [38 41]. 6. Discussion and conclusion In summary, data available on combined HRT and cancer show no effect on endometrial cancer, possibly a reduced risk with continuous combined HRT, a potential increased risk of ovarian cancer (mainly found with ERT, not with HRT), an increased risk of breast cancer with combined HRT, and a protective effect against developing colon cancer. Data available on other types of cancer show no effect or conflicting data. The majority of data available on HRT and breast cancer come from over 60 observational studies [34] and 3 randomized trials [7,30,35] using mostly conjugated equine estrogens via the oral route. These studies provide evidence that either no or a very small increase in the risk of breast cancer appears with current long-term use of combined HRT. It is not clear whether there is a difference in risk with sequentially combined versus continuously combined HRT. Little information is available from prospective randomized trials using different types and doses of estrogen or progestogen, and different routes of administration. It is therefore inappropriate to consider all HRT as being the same. The future of HRT lies in individualization of therapy for each patient. References [1] R. Yancik, L.A. Ries, Cancer in older persons. Magnitude of the problem how do we apply what we know? Cancer 74 (1994) [2] D. Grady, et al., Hormone replacement therapy and endometrial cancer risk: a meta-analysis, Obstet. Gynecol. 85 (1995) [3] S.A. Beresford, et al., Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women, Lancet 349 (1997)
7 P. Kenemans et al. / International Congress Series 1279 (2005) [4] M.C. Pike, et al., Estrogen progestin replacement therapy and endometrial cancer, J. Natl. Cancer Inst. 89 (1997) [5] E. Weiderpass, et al., Risk of endometrial cancer following estrogen replacement with and without progestins, J. Natl. Cancer Inst. 91 (1999) [6] D.A. Hill, et al., Continuous combined hormone replacement therapy and risk of endometrial cancer, Am. J. Obstet. Gynecol. 183 (2000) [7] D. Grady, et al., HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II), JAMA 288 (2002) [8] J.E. Rossouw, et al., Writing Group for the Women s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women s Health Initiative randomized controlled trial, JAMA 288 (2002) [9] S.V. Drew, Oestrogen replacement therapy and ovarian cancer, Lancet 358 (2001) [10] P.P. Garg, et al., Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis, Obstet. Gynecol. 92 (1998) [11] S.S. Coughlin, et al., A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer, J. Clin. Epidemiol. 53 (2000) [12] C. Rodriguez, et al., Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women, JAMA 285 (2001) [13] E. Fernandez, et al., Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies, Int. J. Cancer 105 (2003) [14] I. Persson, et al., Cancer incidence and mortality in women receiving estrogen and estrogen progestin replacement therapy long-term follow-up of a Swedish cohort, Int. J. Cancer 67 (1996) [15] Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer, Lancet 350 (1997) [16] L. Bergkvist, et al., The risk of breast cancer after estrogen and estrogen progestin replacement, N. Engl. J. Med. 321 (1989) [17] I. Persson, et al., Risks of breast and endometrial cancer after estrogen and estrogen progestin replacement, Cancer Causes Control 10 (1999) [18] C. Schairer, et al., Estrogen progestin replacement and risk of breast cancer, JAMA 284 (2000) [19] J.V. Porch, et al., Estrogen progestin replacement therapy and breast cancer risk: the Women s Health Study (United States), Cancer Causes Control. 13 (2002) [20] V. Beral, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study, Lancet 362 (2003) [21] H.L. Olsson, C. Ingvar, A. Bladstrom, Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden, Cancer 97 (2003) [22] C. Stahlberg, Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe, Int. J. Cancer 109 (2004) [23] A. Fournier, et al., Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort, Int. J. Cancer (2004) Nov 18 (Electronic publication ahead of print). [24] C. Magnusson, et al., Breast-cancer risk following long-term oestrogen- and oestrogen progestinreplacement therapy, Int. J. Cancer 81 (1999) [25] R.K. Ross, et al., Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin, J. Natl. Cancer Inst. 92 (2000) [26] C.L. Chen, et al., Hormone replacement therapy in relation to breast cancer, JAMA 287 (2002) [27] P.A. Newcomb, et al., Postmenopausal estrogen and progestin use in relation to breast cancer risk, Cancer Epidemiol. Biomark. Prev. 11 (2002) [28] L.K. Weiss, et al., Hormone replacement therapy regimens and breast cancer risk (1), Obstet. Gynecol. 100 (2002) [29] C.I. Li, et al., Relationship between long durations and different regimens of hormone therapy and risk of breast cancer, JAMA 289 (2003) [30] R.T. Chlebowski, et al., Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women s Health Initiative Randomized trial, JAMA 289 (2003)
8 140 P. Kenemans et al. / International Congress Series 1279 (2005) [31] M.J. van der Mooren, P. Kenemans, The Million Women Study: a license to kill other investigations? Eur. J. Obstet. Gynecol. Reprod. Biol. 113 (2004) 3 5. [32] S. Shapiro, The Million Women Study: potential biases do not allow uncritical acceptance of the data, Climacteric 7 (2004) 3 7. [33] M. Whitehead, R. Farmer, The Million Women Study: a critique, Endocrine 24 (3) (2004) [34] P. Kenemans, A. Bosman, Breast cancer and post-menopausal hormone therapy, Best Pract. Res., Clin. Endocrinol. Metab. 17 (2003) [35] G.L. Anderson, et al., Women s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women s Health Initiative randomized controlled trial, JAMA 291 (2004) [36] K. Nanda, et al., Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis, Obstet. Gynecol. 93 (1999) [37] F. Grodstein, P.A Newcomb, M.J. Stamper, Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis, Am. J. Med. 106 (1999) [38] K. Hunt, M. Vessey, K. McPherson, Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis, Br. J. Obstet. Gynaecol. 97 (1990) [39] S.R. Sturgeon, et al., Evidence of a healthy estrogen user survivor effect, Epidemiology 6 (1995) [40] F. Grodstein, et al., Postmenopausal hormone therapy and mortality, N. Engl. J. Med. 336 (1997) [41] C. Schairer, et al., Cause-specific mortality in women receiving hormone replacement therapy, Epidemiology 8 (1997)
Postmenopausal hormone therapy - cardiac disease risks and benefits
Postmenopausal hormone therapy - cardiac disease risks and benefits Tomi S. Mikkola, MD Helsinki University Central Hospital Department of Obstetrics and Gynecology Helsinki, Finland Disclosures Speaker/consulting
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationPreventing Breast Cancer in HT users by Manuel Neves-e-Castro Portuguese Menopause Society September 2004
Preventing Breast Cancer in HT users by Manuel Neves-e-Castro Portuguese Menopause Society September 2004 I am also PRO!... because HT does not increase breast cancer, and overall, its benefits out weight
More informationA literature review examining the association between the duration of hormone replacement therapy (HRT) and the risk of breast cancer in women
The University of Toledo The University of Toledo Digital Repository Master s and Doctoral Projects A literature review examining the association between the duration of hormone replacement therapy (HRT)
More informationBreast cancer risk with postmenopausal hormonal treatment
Human Reproduction Update, Vol.11, No.6 pp. 545 56, 25 Advance Access publication September 8, 25 doi:1.193/humupd/dmi28 Breast cancer risk with postmenopausal hormonal treatment John A.Collins 1,2,5,
More informationWEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital
WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased
More informationCOMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH. Ross L. Prentice. Fred Hutchinson Cancer Research Center
COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH Ross L. Prentice Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North, M3-A410, POB 19024, Seattle,
More informationHormone therapy. Dr. med. Frank Luzuy
Hormone therapy Dr. med. Frank Luzuy Reasons for Initiating/Continuing HT* Menopause-Related Symptoms Osteoporosis, Bone Loss, Fracture Prevention Doctor Prescribed It, Told Me to Take It Cardiovascular
More informationEstrogen, Estrogen Plus Progestin Therapy, and Risk of Breast Cancer
Vol. 11, 909s 917s, January 15, 2005 (Suppl.) Clinical Cancer Research 909s Estrogen, Estrogen Plus Progestin Therapy, and Risk of Breast Cancer Graham A. Colditz Channing Laboratory, Department of Medicine,
More informationHRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD
Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology
More information1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45
1 2 3 1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women
More informationHaemostasis, thrombosis risk and hormone replacement therapy
Haemostasis, thrombosis risk and hormone replacement therapy Serge Motte Brussels 13.05.17 - MY TALK TODAY The coagulation cascade and its regulation Effects of hormone replacement therapy on haemostasis
More informationHRT, breast and endometrial cancers: strategies and intervention options
Maturitas 32 (1999) 131 139 www.elsevier.com/locate/maturitas HRT, breast and endometrial cancers: strategies and intervention options Piero Sismondi a, *, Nicoletta Biglia a, Maurizia Giai a, Riccardo
More informationBSO, HRT, and ERT. No relevant financial disclosures
BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationCopyright, 1995, by the Massachusetts Medical Society
Copyright, 1995, by the Massachusetts Medical Society Volume 332 JUNE 15, 1995 Number 24 THE USE OF ESTROGENS AND PROGESTINS AND THE RISK OF BREAST CANCER IN POSTMENOPAUSAL WOMEN GRAHAM A. COLDITZ, M.B.,
More informationHT: Where do we stand after WHI?
HT: Where do we stand after WHI? Hormone therapy and cardiovascular disease risk Experimental and clinical evidence indicate that hormone therapy (HT) reduces the risk of cardiovascular disease (CVD) Women
More informationHormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals
Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health
More informationAn overview of menopausal oestrogen progestin hormone therapy and breast cancer risk
British Journal of Cancer (2005) 92, 2049 2058 All rights reserved 0007 0920/05 $30.00 www.bjcancer.com An overview of menopausal oestrogen progestin hormone therapy and breast cancer risk SA Lee*,1, RK
More informationWHI, HERS y otros estudios: Su significado en la clinica diária. Manuel Neves-e-Castro
WHI, HERS y otros estudios: Su significado en la clinica diária III Congreso Ecuatoriano de Climaterio Menopausia y Osteoporosis por Manuel Neves-e-Castro (Lisboa-Portugal) Julho, 2003 Machala The published
More information5. Summary of Data Reported and Evaluation
326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal
More informationCHANGES IN MAMMOGRAPHIC AND ULTRASOUND IMAGE OF THE BREAST OF WOMEN UNDERGOING ESTROGEN REPLACEMENT THERAPY
Biomed. Papers 147(2), 211 219 (2003) D. Houserková, J. Matlochová, M. Hartlová 211 CHANGES IN MAMMOGRAPHIC AND ULTRASOUND IMAGE OF THE BREAST OF WOMEN UNDERGOING ESTROGEN REPLACEMENT THERAPY Dana Houserková
More informationEstrogen and progestogen therapy in postmenopausal women
Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone
More informationHormone therapy (HT) Epidemiological aspects
Hormone therapy (HT) Epidemiological aspects Øjvind Lidegaard Professor, DMSc Gynaecological Clinic 4232 Rigshospitalet Copenhagen University www.lidegaard.dk/slides Hormone therapy; an update Hormone
More informationPostmenopausal hormones and coronary artery disease: potential benefits and risks
CLIMACTERIC 2007;10(Suppl 2):21 26 Postmenopausal hormones and coronary artery disease: potential benefits and risks R. A. Department of Obstetrics and Gynecology, Columbia University, New York, New York,
More informationResearch Article An Estrogen Model: The Relationship between Body Mass Index, Menopausal Status, Estrogen Replacement Therapy, and Breast Cancer Risk
Hindawi Publishing Corporation Computational and Mathematical Methods in Medicine Volume 202, Article ID 792375, 8 pages doi:0.55/202/792375 Research Article An Estrogen Model: The Relationship between
More informationSomething has changed? The literature from 2008 to present?
Something has changed? The literature from 2008 to present? Elina Hemminki National Institute for Health and Welfare, Helsinki, Finland Rome Oct 7, 2011: Post-menopausal hormone therapy and women's information
More informationWHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
More informationSupplementary Online Content
Supplementary Online Content Gartlehner G, Patel SV, Feltner C, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for
More informationAusPharm CE Hormone therapy 23/09/10. Hormone therapy
Hormone therapy Learning objectives: Assess options to address quality of life and health concerns of menopausal women Outline indications for hormone therapy Counsel women on the risks and benefits of
More informationHKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 Revised November BENEFITS OF HRT
HKCOG Guidelines Guidelines for the Administration of Hormone Replacement Therapy Number 2 Revised November 2006 Published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College
More informationHKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 revised January 2003
HKCOG Guidelines Guidelines for the Administration of Hormone Replacement Therapy Number 2 revised January 2003 published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College
More informationJames H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
Disclosure Estrogen Therapy After Postmenopausal Hysterectomy: Issues, Challenges, Risks/Benefits James H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
More informationTHERE IS CONSIDERABLE EVIdence
ORIGINAL CONTRIBUTION Relationship Between Long Durations and Different Regimens of Hormone Therapy and Risk of Breast Cancer Christopher I. Li, MD, PhD Kathleen E. Malone, PhD Peggy L. Porter, MD Noel
More informationIn 1981, we published results from a case-control. study involving 881 cases and 863 controls. not associated with any substantial overall risk,
Br. J. Cancer (1986) 54, 825-832 Menopausal oestrogens and breast cancer risk: An expanded case-control study L.A. Brinton, R. Hoover & J.F. Fraumeni, Jr Environmental Epidemiology Branch, National Cancer
More informationContraception and cancerepidemiological
Contraception and cancerepidemiological evidence Hormonal contraception Combined Progestogen-only Philip C Hannaford University of Aberdeen Breast cancer and combined oral Re-analysis of individual data
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationLessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice
Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and
More informationCancer Risks of Ovulation Induction
Cancer Risks of Ovulation Induction 5th World Congress on Ovulation Induction September 13-15, 2007 Louise A. Brinton, Ph.D. National Cancer Institute Rockville, Maryland, USA Ovulation Induction and Cancer
More informationDiscussing breast cancer and hormone replacement therapy with women
INTERPRETING KEY TRIALS PELIN BATUR, MD Section of Women s Health, Department of General Internal Medicine, Gault Women s Health and Breast Pavilion, The Cleveland Clinic HOLLY L. THACKER, MD, FACP Departments
More informationCLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN
CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN Nanette K. Wenger, MD, is a recognized authority on women and coronary heart disease. She chaired the US National Heart, Lung, and Blood Institute conference
More informationMENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?
MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early
More informationLong-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial
DOI: 10.1111/1471-0528.12598 www.bjog.org Epidemiology Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial
More informationFinancial Conflicts of Interest
Hormone Treatment of Menopausal Women: What Are the Data Telling Us (and Not Telling Us)? S. Mitchell Harman, M.D., Ph.D. Chief, Endocrine Division Phoenix VA Health Care System Clinical Professor, Medicine
More informationMenopausal Hormone Therapy & Haemostasis
Menopausal Hormone Therapy & Haemostasis The Haematologist Perspective Dr. Batia Roth-Yelinek Coagulation unit Hadassah MC Menopausal Hormone Therapy & Hemostasis Hemostatic mechanism Mechanism of estrogen
More information5. Summary of Data Reported and Evaluation
288 5. Summary of Data Reported and Evaluation 5.1 Exposure Oral contraceptives have been used since the early 1960s and are now used by about 90 million women worldwide. The pill is given as a combination
More informationIs It Time To Implement Ovarian Cancer Screening?
Is It Time To Implement Ovarian Cancer Screening? Prof Dr Samet Topuz Istanbul Medıcal Faculty Department Of Obstetrics and Gynecology ESGO Prevention in Gynaecological Malignancies September 08 2016 Antalya
More informationManagement of Perimenopausal symptoms
Management of Perimenopausal symptoms Serge Rozenberg CHU St Pierre Université libre de Bruxelles Belgium serge_rozenberg@stpierre-bru.be serge.rozenberg@skynet.be Conflict of interest & Disclosure Conflicts
More informationThe Practice Committee of the American Society for Reproductive Medicine,
FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. PRACTICE COMMITTEE Estrogen
More informationControversies in Primary Care Pros and Cons of HRT on patients with CHD
Controversies in Primary Care Pros and Cons of HRT on patients with CHD Claire Bellone MSc Clinical Nurse Specialist Menopause Nottingham Declaration Honorariums & Sponsorship from Bayer, Novonortis, Wyeth
More informationHysterectomy with Preservation of both Ovaries does not Result in Premature Ovarian Failure
The Journal of International Medical Research 2007; 35: 416 421 Hysterectomy with Preservation of both Ovaries does not Result in Premature Ovarian Failure V ATAY 1, T CEYHAN 2, İ BASER 2, S GUNGOR 2,
More informationNew Insights into Breast Cancer Risk Reduction
New Insights into Breast Cancer Risk Reduction November 10, 2013 Rowan T. Chlebowski Professor of Medicine David Geffen School of Medicine at UCLA Chief, Division of Medical Oncology and Hematology Harbor-UCLA
More informationSupplementary Table 4. Study characteristics and association between OC use and endometrial cancer incidence
Supplementary Table 4. characteristics and association between OC use and endometrial cancer incidence a Details OR b 95% CI Covariates Region Case-control Parslov, 2000 (1) Danish women aged 25 49 yr
More informationHORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer
HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy
More informationEffects of a short-term suspension of hormone replacement therapy on mammographic density
FERTILITY AND STERILITY VOL. 76, NO. 3, SEPTEMBER 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effects of a short-term
More informationIJC International Journal of Cancer
IJC International Journal of Cancer Postmenopausal hormone therapy and the risk of breast cancer in Norway Marta Roman 1,2, Solveig Sakshaug 3, Sidsel Graff-Iversen 4, Siri Vangen 2, Elisabete Weiderpass
More informationCurrent Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes
Current Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes The Northern California Kaiser Permanente Diabetes Registry, 1995 1998
More information9/27/2017. Disclosure. Selecting Progestogens: Breast, Cardiovascular, and Cognitive Outcomes. James H Liu, MD. Overview
Disclosure Selecting Progestogens: Breast, Cardiovascular, and Cognitive utcomes James H Liu, MD Arthur H Bill Professor and Chair Departments of Reproductive Biology and bstetrics and Gynecology UH Cleveland
More informationORIGINAL INVESTIGATION. Hormone Therapy and the Impact of Estrogen Intake on the Risk of Ovarian Cancer. increasingly used in developed
ORIGINAL INVESTIGATION Hormone Therapy and the Impact of Estrogen Intake on the Risk of Ovarian Cancer Eva Glud, MD, PhD; Susanne K. Kjaer, DMSc; Birthe L. Thomsen, MSc; Claus Høgdall, PhD; Lise Christensen,
More informationIncreased breast carcinoma risk is a major concern for women. Hormone Replacement Therapy in Relation to Breast Carcinoma Incidence Rate Ratios
2328 Hormone Replacement Therapy in Relation to Breast Carcinoma Incidence Rate Ratios A Prospective Danish Cohort Study Anne Tjønneland, Ph.D. 1 Jane Christensen, M.Sc. 1 Birthe L. Thomsen, M.Sc. 1 Anja
More informationPost-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018
Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma
More informationH Jernström, J Frenander, M Fernö and H Olsson
Article no. bjoc.1999.0543 Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients H Jernström,
More informationHow HRT Hurts the Heart
How HRT Hurts the Heart Coronary artery disease (CAD) is a killer and recent studies have come up with evidence that HRT might have a role in increasing CAD among women. Why? Zaheer Lakhani, MD, FRCP For
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Predicting the menopause The menopause marks the end of ovarian follicular activity and is said to have occurred after 12 months amenorrhoea. The average age of the menopause is between 45 and 60 years
More informationLow & Ultra Low Dose HRT The Cardiovascular Impact
Low & Ultra Low Dose HRT The Cardiovascular Impact Wyeth Symposium, Turin 29 th Sept 2007 Nick Panay Consultant Gynaecologist Queen Charlotte s & Chelsea and Chelsea & Westminster Hospitals Honorary Senior
More informationLong-term Postmenopausal Hormone Therapy and Endometrial Cancer
Research Article Long-term Postmenopausal Hormone Therapy and Endometrial Cancer Cancer Epidemiology, Biomarkers & Prevention Pedram Razavi 1, Malcolm C. Pike 1, Pamela L. Horn-Ross 2, Claire Templeman
More informationOutline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013
Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort
More informationDisclosure Information Relationships Relevant to this Session
Disclosure Information Relationships Relevant to this Session DeCensi, Andrea No relevant relationships to disclose. Please note, all disclosures are reported as submitted to ASCO, and are always available
More informationIARC Monographs Program on Carcinogenicity of Combined Hormonal Contraceptives and Menopausal Therapy
Presidential comment IARC Monographs Program on Carcinogenicity of Combined Hormonal Contraceptives and Menopausal Therapy H. P. G. Schneider, President of the IMS, in co-operation with A. O. Mueck* and
More informationA prospective study of postmenopausal hormone use and ovarian cancer risk
British Journal of Cancer (2007) 96, 151 156 All rights reserved 0007 0920/07 $30.00 www.bjcancer.com A prospective study of postmenopausal hormone use and ovarian cancer risk KN Danforth*,1, SS Tworoger
More informationWHI, Nurses and SWANs: Do Big Clinical Trials Inform Personalized Care? KIRTLY PARKER JONES MD
WHI, Nurses and SWANs: Do Big Clinical Trials Inform Personalized Care? KIRTLY PARKER JONES MD Conflicts? No financial conflicts of interest (Dr. Jones is a post menopausal female reproductive endocrinologist
More informationHormone Replacement Therapy (HRT) Benefits & Risks - The Facts
Hormone Replacement Therapy (HRT) Benefits & Risks - The Facts HRT is a prescription only treatment that replaces some of the lost oestrogen and progesterone hormones which occur during menopause. It can
More informationPotential dangers of hormone replacement therapy in women at high risk
ESC meeting, Stockholm, August 30, 16.30-18.00, 2010 Potential dangers of hormone replacement therapy in women at high risk Karin Schenck-Gustafsson MD, PhD, FESC Professor, Chief consultant Department
More informationPOSTMENOPAUSAL ESTROGEN USE
ORIGINAL CONTRIBUTION Estrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US Women Carmen Rodriguez, MD, MPH Alpa V. Patel, MPH Eugenia E. Calle, PhD Eric J. Jacob,
More informationHRT & Menopause Where Do We Stand Now?
HRT & Menopause Where Do We Stand Now? Mrs. SY Hussain Consultant Gynaecologist The Holly Private Hospital Spire Roding Hospital The Wellington Hospital Discussion Points Discuss Recommendations made by
More informationNorth American Menopause Society (NAMS)
North American Menopause Society (NAMS) 2012 Hormone Therapy Position Statement Cynthia B. Evans, MD Assistant Professor-Clinical Department of Obstetrics and Gynecology The Ohio State University College
More informationMenopause and Cancer risk; What to do overcome the risks? Fatih DURMUŞOĞLU,M.D
Menopause and Cancer risk; What to do overcome the risks? Fatih DURMUŞOĞLU,M.D Menopause and Cancer How does menopause affect a woman s cancer risk? Ø Menopause does not cause cancer.but risk of developing
More informationHormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial
European Journal of Cancer (2013) 49, 52 59 Available at www.sciencedirect.com journalhomepage:www.ejcancer.info Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised
More informationRisk-reducing surgery and hormones
Risk-reducing surgery and hormones Nora Johansen Registrar and PhD student at Department of Obstetrics and Gynecology, Sørlandet Hospital Arendal, Norway No conflicts of interest to declare Overview Hereditary
More informationAmerican Journal of Internal Medicine
American Journal of Internal Medicine 2016; 4(3): 49-59 http://www.sciencepublishinggroup.com/j/ajim doi: 10.11648/j.ajim.20160403.12 ISSN: 2330-4316 (Print); ISSN: 2330-4324 (Online) The Effect of Dose-Reduced
More informationSERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationHormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare
Hormones friend or foe? Undertreatment and quality of life Anette Tønnes Pedersen MD, Ph.D. Consultant, Associate professor Dept. Of Gynecology / Fertility Clinic Rigshospitalet No conflicts of interest
More informationTHE POSSIBLE ASSOCIATION BEtween
ORIGINAL CONTRIBUTION Hormone Replacement Therapy in Relation to Breast Cancer Chi-Ling Chen, PhD Noel S. Weiss, MD, DrPH Polly Newcomb, PhD William Barlow, PhD Emily White, PhD THE POSSIBLE ASSOCIATION
More informationMenopause and HRT. John Smiddy and Alistair Ledsam
Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation
More informationBASED ON CONCERNS that estrogen replacement
Estrogen Replacement Therapy After Localized Breast Cancer: Clinical Outcome of 319 Women Followed Prospectively By Rena Vassilopoulou-Sellin, Lina Asmar, Gabriel N. Hortobagyi, Mary Jean Klein, Marsha
More informationThe relationship between mammographic density and duration of hormone therapy: effects of estrogen and estrogen progestin
Human Reproduction Vol.20, No.6 pp. 1741 1745, 2005 Advance Access publication April 21, 2005 doi:10.1093/humrep/deh820 The relationship between mammographic density and duration of hormone therapy: effects
More informationPresentation to the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Therapy
Presentation to the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Therapy March 5, 2019 Nese Yuksel, BScPharm, PharmD, FCSHP, NCMP Professor Faculty of Pharmacy and Pharmaceutical
More informationHyperandrogenism, PCOS and obesity after menopause : Meet the experts. Polycystic ovaries beyond menopause
Hyperandrogenism, PCOS and obesity after menopause : Meet the experts Polycystic ovaries beyond menopause Serge Rozenberg CHU St Pierre Université libre de Bruxelles, Vrije Universiteit Brussel Belgium
More informationThe preferred treatment for osteoporosis
Alternate Options to Hormone Replacement Therapy for Osteoporosis James R. Shoemaker, DO Andrea B. Klemes, DO This presentation, developed from a symposium lecture at the 40th Annual Convention of the
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1997, by the Massachusetts Medical Society VOLUME 336 J UNE 19, 1997 NUMBER 25 POSTMENOPAUSAL HORMONE THERAPY AND MORTALITY FRANCINE GRODSTEIN, SC.D., MEIR
More informationHealth Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. The WHI Investigators
Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin The WHI Investigators 1 Background: WHI Hormone Program Design YES N= 10,739 Conjugated equine estrogen
More informationGallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study
Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study Bette Liu, Valerie Beral, Angela Balkwill, Jane Green, Siân Sweetland,
More informationVirtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11
Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,
More informationPrior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD
Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD JoAnn V. Pinkerton, MD Professor of Obstetrics and Gynecology Director,
More informationFinding Our Reasons to Choose Estrogen PRE- HRT. Learning Objectives. Disclosure. Learning Objectives. Replacement Therapy. For Previvors 6/1/17
Hormone Replacement Therapy Mefile:///Reimagined: How to Look Hot and Feel Healthy For Previvors Without Fear and Confusion Mache Seibel, MD HRT PRE- FOR VIVORS Mache Seibel, MD DrMache.com Disclosure
More informationChemo-endocrine prevention of breast cancer
Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;
More informationTHE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY
Annu. Rev. Public Health 2005. 26:115 40 doi: 10.1146/annurev.publhealth.26.021304.144637 Copyright c 2005 by Annual Reviews. All rights reserved THE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY Elizabeth
More informationModeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L
Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L Record Status This is a critical abstract of an economic
More informationPractical recommendations for hormone replacement therapy in the peri- and postmenopause
CLIMACTERIC 2004;7:in press Practical recommendations for hormone replacement therapy in the peri- and postmenopause Recommendations from an Expert Workshop, February 2004 Henry Burger, Australia; David
More information